Carlini, Federico
Ivaldi, Federico
Gualandi, Francesca
Boschert, Ursula
Centonze, Diego
Matarese, Giuseppe
Salvetti, Marco
Kerlero de Rosbo, Nicole
Uccelli, Antonio http://orcid.org/0000-0002-2008-6038
Funding for this research was provided by:
Merck KGaA
Università degli Studi di Genova
Article History
Received: 12 January 2020
Accepted: 31 March 2021
First Online: 14 April 2021
Declarations
:
: The study was approved by the Institutional Review Board of the University of Genoa (041REG2016). Donors provided their signed informed consent before enrolment in the study according to the Declaration of Helsinki.
: F. Carlini, F. Ivaldi, F. Gualandi, and N. Kerlero de Rosbo report no conflicts of interest. A. Uccelli has received consulting honoraria including as part of advisory board and/or speaker fees from Sanofi Genzyme, Roche, Biogen, Novartis, TEVA and Merck. D. Centonze is an Advisory Board member of Actelion, Almirall, Celgene, BMS, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva. He has received honoraria for speaking or consultation fees from Almirall, Bayer Schering, Biogen, BMS, GW Pharmaceuticals, Lundbeck, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva. He is also a principal investigator in clinical trials for Abbvie, Bayer Schering, Biogen, Merck Serono, Mitsubishi, Novartis, Roche, Sanofi-Genzyme and Zambon. His preclinical and clinical research has been supported by grants from Bayer Schering, Biogen, Celgene, Lundbeck, Merck Serono, Novartis, Roche, Sanofi-Genzyme and Teva. G. Matarese reports receiving research grant support from Merck, Biogen and Novartis and advisory board fees from Merck, Biogen, Novartis and Roche. M. Salvetti has received speaking honoraria, consulting fees and research support from Merck, Sanofi, Novartis, Roche, Biogen. U. Boschert is an employee of Ares Trading SA, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.